Criteria for NGS testing in MNs can reduce unnecessary tests, saving costs without affecting patient care quality. Six approval and six cancellation criteria guide appropriate NGS use, focusing on ...

Patients with TP53/PPM1D mutations in their stem cell product had an increased risk of myeloid neoplasms in patients with Hodgkin lymphoma undergoing autologous stem cell transplant. While autologous ...

Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma Therapy-related myeloid neoplasm (t-MN) ...

A new editorial paper was published in Oncotarget's Volume 15 on July 2, 2024, entitled, "DDX41 and its unique contribution to myeloid leukemogenesis." In this new editorial, researcher Hirotaka ...

“[...] myeloid neoplasms associated with DDX41 variants likely exhibit a unique pathogenesis that diverges from the conventional understanding of myeloid neoplasms ...

The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as ...

The prognosis for patients with myeloid/lymphoid neoplasms with FGFR1 rearrangements is poor, and treatment options are limited. In a phase II study of these patients, the overall complete response ...

(a) Peripheral blood smear in a patient with the chronic phase of chronic myeloid leukemia (CML) before treatment; (b) Detection of BCR::ABL1 fusion gene, p210 by RNA sequencing; (c) Peripheral blood ...